Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Yakuhin To Sell Kobe Research Lab (Japan)

This article was originally published in PharmAsia News

Executive Summary

Bayer Yakuhin Ltd., a Japanese subsidiary of German pharmaceutical firm Bayer Schering Pharma AG, plans to close a Kobe research laboratory before the end of the year and sell it. The move is part of Bayer's effort to streamline operations after it acquired last year German drugmaker Schering AG and in July consolidated the two firms' Japanese units. The lab has been involved in basic research, including stem cell cultivation, achieving some breakthroughs. Following the merger, however, Bayer Schering decided to concentrate research on cancer, heart disease, gynecological disorders and diagnostic imaging drugs. (Click here for more - May Require Paid Subscription

You may also be interested in...



Bayer Shering Pharma Applies For iPS Patent With Japan Patent Office

TOKYO - Bayer Shering Pharma AG has submitted patent applications for its induced pluripotent stem cell manufacturing method with the Japan Patent Office, the first foreign entity to seek intellectual property rights protection for an iPS method after one filed by Kyoto University Professor Shinya Yamanaka, according to Bayer's patent filing released by JPO Dec. 25, 2008

What To Consider For German Orphan Drug Price Negotiations

The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.

Viatris’ UpJohn Breaking Taboo Around Erectile Dysfunction With UK PR Campaign

Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals. 

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel